towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
p38 and JNK induction by TRAIL<br />
rabbit‐IRDye (800CW;926‐32211 and 680;#926‐32221) were used. Protein expression was<br />
visualized with the Odyssey Infrared Imager (Westburg, Leusden, the Netherlands), at a 84<br />
µm resolution, 0 mm offset and with high quality [17].<br />
RNA interference<br />
H460 cells were plated at a density of 7.5 x10 4<br />
cells in 6‐well tissue culture plates and<br />
allowed to attach overnight. The next day, cells were incubated with serum‐free medium<br />
and transfected with 100 nM SignalSilence® p38 MAPK siRNA I (#6564), 100 nM<br />
SignalSilence® SAPK/JNK siRNA I (#6232), SignalSilence® Control siRNA (Fluorescein<br />
Conjugate) (#6201) (all from Cell Signaling Technology Inc), 20 pmol Mcl‐1 siRNA<br />
(Dharmacon, M‐004501‐08) or scrambled siRNA (Invitrogen) using Lipofectamine 2000<br />
(Invitrogen) according to the manufacturer’s protocol. Cells were then incubated <strong>for</strong> a<br />
minimum of 24 h be<strong>for</strong>e assaying <strong>for</strong> expression.<br />
For short hairpin (sh)RNA mediated silencing pSUPER.retro plasmid was used similarly as<br />
described previously [18]. Targeted shRNA sequences were inserted into the BglII and<br />
HindIII sites of the pSUPER.retro vector. All cloned shRNA sequences were verified by DNA<br />
sequencing. Retroviruses were packaged and introduced into cells as described previously<br />
[19]. H460 cells were retrovirally infected with control pSUPER.retro or pSUPER.retro‐<br />
shRIP1 (RIP1‐targeting sequence #1, 5'‐ GAGCAGCAGTTGATAATGT‐3'; RIP1‐targeting<br />
sequence #2 5'‐ TACCACTAGTCTGACGGATAA‐3') <strong>for</strong> 24 h. Infected cells were selected with<br />
2 µg/ml puromycin.<br />
Quantitative RT‐PCR<br />
Total RNA was extracted using the QiaAmp RNA mini‐Kit (Qiagen, San Diego, CA), and<br />
yields and purity were checked at 260‐280 nm with NanoDrop®‐1000‐Detector<br />
(NanoDrop‐Technologies, Wilmington, NC). RNA (500 ng) was reverse transcribed using<br />
the DyNAmo cDNA Synthesis Kit (Thermo Scientific, Vantaa, Finland), according to the<br />
manufacturers’ instruction. Primers and probes to specifically amplify Mcl‐1 and Bcl‐2<br />
were obtained from Applied Biosystems Assay‐on‐Demand Gene expression products<br />
(Hs01050896_m1, and Hs00608023_m1). The real‐time quantitative PCR was per<strong>for</strong>med in<br />
a 25 μl reaction volume containing TaqMan Universal master mix (Applied Biosystems,<br />
Forster City, CA). All reactions were per<strong>for</strong>med in triplicate using the ABI PRISM 7500<br />
sequence detection system instrument (Applied Biosystems). Samples were amplified<br />
using the following thermal profile: 50 °C <strong>for</strong> 2 min, 95 °C <strong>for</strong> 10 min, 40 cycles of<br />
denaturation at 95 °C <strong>for</strong> 15 sec followed by annealing and extension at 60 °C <strong>for</strong> 1 min.<br />
Amplifications were normalized to β‐actin, whose values were the closest to the geometric<br />
mean values observed <strong>for</strong> three housekeeping genes in preliminary analysis. Preliminary<br />
experiments were carried out with dilutions of cDNA obtained from Quantitative PCR<br />
Human Reference Total RNA (Stratagene, La Jolla, CA) to demonstrate that the efficiencies<br />
‐ 43 ‐